Early on December 9 - a Saturday - the US House of Representatives passed S 3678, the Pandemic and All-Hazards Preparedness Act.
Welcoming the move, Biotechnology Industry Organization president Jim Greenwood said: "this bill includes critical Biomedical Advanced Research and Development Authority (BARDA) provisions and provisions to reauthorize bioterrorism grants and is a necessary step toward improving America's defenses against bioterrorism and pandemic diseases." This legislation recognizes that there remains a barrier to effective countermeasure product development, and authorizes the BARDA within the Department of Health and Human Services. Through this, contracts and grants for advanced R&D will be made to firms working on products to protect US citizens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze